IQVIA conducted a thorough ... Integrating the patient journey Failures in patient engagement and retention can delay or stop a clinical trial. DCT studies are proving to be helpful with this ...

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...

IQVIA introduced a suite of clinical technology solutions that can speed clinical trials while reducing burden on patients, and also empower the company to utilize data more strategically.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services ... regulatory compliance, and patient safety. IQVIA Healthcare-grade ...